MONTREAL, October 12th, 2022 – Replicor Inc., presented data indicating the broad-spectrum antiinflammatory properties of REP 2139 at the 2022 Delta Cure Meeting held October 6-7, 2022 in Milan, Italy (see here).
Target interaction of nucleic acid polymers (NAPs) occurs via a unique drug interface (see here) previously shown to be present in type 1 viral glycoproteins, HDAg and most recently the HSP40 chaperone DNAJB12 which is critical for SVP assembly. Analogous target interfaces are also present in a variety of proinflammatory cytokines and chemokines which drive high affinity NAP interactions with these molecules (see here).
Dr. Andrew Vaillant commented, “The safety and tolerability of host mediated transaminase flares during NAP therapy, the improved tolerability of pegIFN with REP 2139 and the recent observations of rapid reversal of ascites prior to antiviral response in our compassionate use program suggests hepatoprotective capabilities of REP 2139 in addition to its antiviral effects. The interactions of NAPs with pro-inflammatory cytokines / chemokines suggest an anti-inflammatory activity accompanying the liver accumulation of REP 2139 which is consistent with these clinical observations.”
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further
information about Replicor please visit our website at www.replicor.com.